Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2023

(marketscreener.com) Appili completes strategic reprioritization of programs to focus on ATI-1701, a biodefense tularemia vaccine candidate, ATI-1801, a topical antiparasitic product for the treatment of a disfiguring disease, and ATI-1501, a liquid oral formulation of the antibiotic metronidazole.https://www.marketscreener.com/quote/stock/APPILI-THERAPEUTICS-INC-60546364/news/Appili-Therapeutics-Reports-Financial-and-Operational-Results-for-Second-Quarter-of-Fiscal-Year-2023-42269908/?utm_medium=RSS&utm_content=20221110